John D. Lapek
Pfizer (United States)(US)Kratos Defense & Security Solutions (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Cancer-related Molecular Pathways, Advanced Breast Cancer Therapies, Advanced Proteomics Techniques and Applications, Protease and Inhibitor Mechanisms
Most-Cited Works
- → Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer(2018)517 cited
- → Essential metabolism for a minimal cell(2019)185 cited
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities(2017)167 cited
- → Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity(2023)160 cited
- → Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer(2021)112 cited
- → Reversible lysine-targeted probes reveal residence time-based kinase selectivity